Company profile
STOKE THERAPEUTICS, INC.
NASDAQ:STOKBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZOREVUNERSEN | phase3 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06872125 | phase3 | recruiting | 2025-06-04 | 2027-03-01 | Stoke Therapeutics, Inc | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome |
| NCT04740476 | phase2 | active_not_recruiting | 2021-01-20 | 2029-03-31 | Stoke Therapeutics, Inc | An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome |
| NCT04442295 | phase1_2 | completed | 2020-06-29 | 2023-11-14 | Stoke Therapeutics, Inc | An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome |
FDA applications (0)
No records yet.